Human Vaccine Market Size, Share, Trends, Growth Outlook

Human Vaccine Market is estimated to increase at a growth rate of 8.5% CAGR over the forecast period from 2024 to 2030.

The global Human Vaccine Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Technology (Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Others), By Type (Monovalent Vaccines, Mulitvalent Vaccines ), By Route of Administration (Intramuscular, Subcutaneous, Oral), By End-User (Pediatrics, Adults), By Indication (Pneumococcal Disease, Influenza, Combination Vaccines, HPV, Meningococcal Disease, Herpes Zoster , Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, Others).

An Introduction to Human Vaccine Market in 2024

The Human Vaccine Market encompasses a wide range of preventive vaccines, prophylactic immunizations, and vaccination programs targeting infectious diseases, viral infections, bacterial infections, and emerging pathogens in humans. This market includes pediatric vaccines, adult vaccines, travel vaccines, seasonal vaccines, and pandemic vaccines designed to induce protective immunity, reduce disease transmission, and prevent vaccine-preventable illnesses. Innovations in the human vaccine market focus on novel vaccine platforms, adjuvant technologies, mRNA vaccines, DNA vaccines, and therapeutic vaccines targeting cancer, autoimmune diseases, and chronic infections to address global health challenges, enhance vaccination coverage, and improve public health outcomes.

Human Vaccine Market Competitive Landscape

The global Human Vaccine Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Human Vaccine Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Human Vaccine Industry include- AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd, BioNTech SE, CanSino Biologics Inc, CSL Ltd, Daiichi Sankyo Co. Ltd, Emergent BioSolutions Inc, GlaxoSmithKline Plc, Gradalis Inc, Inovio Pharmaceuticals Inc, Johnson and Johnson, Merck and Co. Inc, Mitsubishi Chemical Group Corp, Moderna Inc, Novavax Inc, Pfizer Inc, Sanofi S.A., Serum Institute of India Pvt. Ltd.

Human Vaccines Market Trend: Advancements in Vaccine Technology and Manufacturing

In the market for Human Vaccines, a prominent trend is the continuous advancements in vaccine technology and manufacturing processes. This trend encompasses the development of novel vaccine platforms, such as mRNA vaccines, and improvements in manufacturing efficiency and scalability. These advancements are driving innovation in vaccine development, enabling the rapid response to emerging infectious diseases and enhancing the efficacy of existing vaccines.

Human Vaccines Market Driver: Growing Awareness of the Importance of Immunization

A key driver in the Human Vaccine market is the growing awareness of the importance of immunization in preventing infectious diseases. Public health campaigns, education initiatives, and expanded vaccination programs worldwide have contributed to increased vaccination rates across different age groups and demographics. The recognition of vaccines as a vital tool in disease prevention, coupled with the rising prevalence of infectious diseases, fuels the demand for vaccines and drives market growth.

Human Vaccines Market Opportunity: Expansion of Vaccine Access and Distribution Networks

An opportunity exists in the expansion of vaccine access and distribution networks to underserved regions and populations. This opportunity involves leveraging innovative delivery mechanisms, such as microneedle patches and oral vaccines, to overcome logistical challenges and improve vaccine coverage. Furthermore, partnerships between pharmaceutical companies, non-profit organizations, and government agencies can facilitate the equitable distribution of vaccines, ensuring that all individuals have access to life-saving immunization services.

Human Vaccine Market Share Analysis: Recombinant Vaccines is the fastest growing market segment over the forecast period to 2030

Recombinant vaccines are developed using genetic engineering techniques to produce antigens or proteins that mimic those found on the surface of pathogens, stimulating the immune system to generate a protective response. This technology offers several advantages over traditional vaccine production methods, including improved safety, scalability, and the ability to precisely target specific antigens. Recombinant vaccines have demonstrated efficacy in preventing a wide range of infectious diseases, including influenza, hepatitis B, and human papillomavirus (HPV). Additionally, ongoing advancements in biotechnology and vaccine development have accelerated the research and production of recombinant vaccines, leading to the introduction of novel formulations and expanded vaccine coverage. The growing demand for vaccines with enhanced safety profiles and broader protection against infectious diseases is driving the rapid growth of the Recombinant Vaccines segment. As a result, this segment is emerging as the fastest-growing category in the human vaccine market, offering innovative solutions to address global public health challenges.

Human Vaccine Market Segmentation

By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Route of Administration
Intramuscular
Subcutaneous
Oral
By End-User
Pediatrics
Adults
By Indication
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Human Vaccine Companies

AstraZeneca Plc
Bavarian Nordic AS
Bharat Biotech Ltd
BioNTech SE
CanSino Biologics Inc
CSL Ltd
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc
GlaxoSmithKline Plc
Gradalis Inc
Inovio Pharmaceuticals Inc
Johnson and Johnson
Merck and Co. Inc
Mitsubishi Chemical Group Corp
Moderna Inc
Novavax Inc
Pfizer Inc
Sanofi S.A.
Serum Institute of India Pvt. Ltd
* List not Exhaustive

Reasons to Buy the Human Vaccine Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Human Vaccine Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Human Vaccine Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Human Vaccine Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Human Vaccine Market Size Outlook, $ Million, 2021 to 2030
3.2 Human Vaccine Market Outlook by Type, $ Million, 2021 to 2030
3.3 Human Vaccine Market Outlook by Product, $ Million, 2021 to 2030
3.4 Human Vaccine Market Outlook by Application, $ Million, 2021 to 2030
3.5 Human Vaccine Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Human Vaccine Industry
4.2 Key Market Trends in Human Vaccine Industry
4.3 Potential Opportunities in Human Vaccine Industry
4.4 Key Challenges in Human Vaccine Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Human Vaccine Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Human Vaccine Market Outlook by Segments
7.1 Human Vaccine Market Outlook by Segments, $ Million, 2021- 2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Route of Administration
Intramuscular
Subcutaneous
Oral
By End-User
Pediatrics
Adults
By Indication
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
8 North America Human Vaccine Market Analysis and Outlook To 2030
8.1 Introduction to North America Human Vaccine Markets in 2024
8.2 North America Human Vaccine Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Human Vaccine Market size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Route of Administration
Intramuscular
Subcutaneous
Oral
By End-User
Pediatrics
Adults
By Indication
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
9 Europe Human Vaccine Market Analysis and Outlook To 2030
9.1 Introduction to Europe Human Vaccine Markets in 2024
9.2 Europe Human Vaccine Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Human Vaccine Market Size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Route of Administration
Intramuscular
Subcutaneous
Oral
By End-User
Pediatrics
Adults
By Indication
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
10 Asia Pacific Human Vaccine Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Human Vaccine Markets in 2024
10.2 Asia Pacific Human Vaccine Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Human Vaccine Market size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Route of Administration
Intramuscular
Subcutaneous
Oral
By End-User
Pediatrics
Adults
By Indication
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
11 South America Human Vaccine Market Analysis and Outlook To 2030
11.1 Introduction to South America Human Vaccine Markets in 2024
11.2 South America Human Vaccine Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Human Vaccine Market size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Route of Administration
Intramuscular
Subcutaneous
Oral
By End-User
Pediatrics
Adults
By Indication
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
12 Middle East and Africa Human Vaccine Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Human Vaccine Markets in 2024
12.2 Middle East and Africa Human Vaccine Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Human Vaccine Market size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Route of Administration
Intramuscular
Subcutaneous
Oral
By End-User
Pediatrics
Adults
By Indication
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AstraZeneca Plc
Bavarian Nordic AS
Bharat Biotech Ltd
BioNTech SE
CanSino Biologics Inc
CSL Ltd
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc
GlaxoSmithKline Plc
Gradalis Inc
Inovio Pharmaceuticals Inc
Johnson and Johnson
Merck and Co. Inc
Mitsubishi Chemical Group Corp
Moderna Inc
Novavax Inc
Pfizer Inc
Sanofi S.A.
Serum Institute of India Pvt. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Route of Administration
Intramuscular
Subcutaneous
Oral
By End-User
Pediatrics
Adults
By Indication
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others